310 related articles for article (PubMed ID: 29750281)
1. An orthotopic glioblastoma animal model suitable for high-throughput screenings.
Pudelko L; Edwards S; Balan M; Nyqvist D; Al-Saadi J; Dittmer J; Almlöf I; Helleday T; Bräutigam L
Neuro Oncol; 2018 Oct; 20(11):1475-1484. PubMed ID: 29750281
[TBL] [Abstract][Full Text] [Related]
2. Identify a Blood-Brain Barrier Penetrating Drug-TNB using Zebrafish Orthotopic Glioblastoma Xenograft Model.
Zeng A; Ye T; Cao D; Huang X; Yang Y; Chen X; Xie Y; Yao S; Zhao C
Sci Rep; 2017 Oct; 7(1):14372. PubMed ID: 29085081
[TBL] [Abstract][Full Text] [Related]
3. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.
Visnyei K; Onodera H; Damoiseaux R; Saigusa K; Petrosyan S; De Vries D; Ferrari D; Saxe J; Panosyan EH; Masterman-Smith M; Mottahedeh J; Bradley KA; Huang J; Sabatti C; Nakano I; Kornblum HI
Mol Cancer Ther; 2011 Oct; 10(10):1818-28. PubMed ID: 21859839
[TBL] [Abstract][Full Text] [Related]
4. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
5. AshwaMAX and Withaferin A inhibits gliomas in cellular and murine orthotopic models.
Chang E; Pohling C; Natarajan A; Witney TH; Kaur J; Xu L; Gowrishankar G; D'Souza AL; Murty S; Schick S; Chen L; Wu N; Khaw P; Mischel P; Abbasi T; Usmani S; Mallick P; Gambhir SS
J Neurooncol; 2016 Jan; 126(2):253-64. PubMed ID: 26650066
[TBL] [Abstract][Full Text] [Related]
6. ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
Cam M; Charan M; Welker AM; Dravid P; Studebaker AW; Leonard JR; Pierson CR; Nakano I; Beattie CE; Hwang EI; Kambhampati M; Nazarian J; Finlay JL; Cam H
Neuro Oncol; 2020 Mar; 22(3):345-356. PubMed ID: 31763674
[TBL] [Abstract][Full Text] [Related]
7. Standardized orthotopic xenografts in zebrafish reveal glioma cell-line-specific characteristics and tumor cell heterogeneity.
Welker AM; Jaros BD; Puduvalli VK; Imitola J; Kaur B; Beattie CE
Dis Model Mech; 2016 Feb; 9(2):199-210. PubMed ID: 26659251
[TBL] [Abstract][Full Text] [Related]
8. Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.
Ferrandon S; Malleval C; El Hamdani B; Battiston-Montagne P; Bolbos R; Langlois JB; Manas P; Gryaznov SM; Alphonse G; Honnorat J; Rodriguez-Lafrasse C; Poncet D
Mol Cancer; 2015 Jul; 14():134. PubMed ID: 26183089
[TBL] [Abstract][Full Text] [Related]
9. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
Radaelli E; Ceruti R; Patton V; Russo M; Degrassi A; Croci V; Caprera F; Stortini G; Scanziani E; Pesenti E; Alzani R
Histol Histopathol; 2009 Jul; 24(7):879-91. PubMed ID: 19475534
[TBL] [Abstract][Full Text] [Related]
10. Improving zebrafish embryo xenotransplantation conditions by increasing incubation temperature and establishing a proliferation index with ZFtool.
Cabezas-Sainz P; Guerra-Varela J; Carreira MJ; Mariscal J; Roel M; Rubiolo JA; Sciara AA; Abal M; Botana LM; López R; Sánchez L
BMC Cancer; 2018 Jan; 18(1):3. PubMed ID: 29291719
[TBL] [Abstract][Full Text] [Related]
11. Quantification of glioblastoma progression in zebrafish xenografts: Adhesion to laminin alpha 5 promotes glioblastoma microtumor formation and inhibits cell invasion.
Gamble JT; Reed-Harris Y; Barton CL; La Du J; Tanguay R; Greenwood JA
Biochem Biophys Res Commun; 2018 Dec; 506(4):833-839. PubMed ID: 30389143
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma research on zebrafish xenograft models: a systematic review.
Pliakopanou A; Antonopoulos I; Darzenta N; Serifi I; Simos YV; Katsenos AP; Bellos S; Alexiou GA; Kyritsis AP; Leonardos I; Vezyraki P; Peschos D; Tsamis KI
Clin Transl Oncol; 2024 Feb; 26(2):311-325. PubMed ID: 37400666
[TBL] [Abstract][Full Text] [Related]
13. PRMT5 as a druggable target for glioblastoma therapy.
Banasavadi-Siddegowda YK; Welker AM; An M; Yang X; Zhou W; Shi G; Imitola J; Li C; Hsu S; Wang J; Phelps M; Zhang J; Beattie CE; Baiocchi R; Kaur B
Neuro Oncol; 2018 May; 20(6):753-763. PubMed ID: 29106602
[TBL] [Abstract][Full Text] [Related]
14. Antitumor compound testing in glioblastoma organotypic brain cultures.
Biggs T; Foreman J; Sundstrom L; Regenass U; Lehembre F
J Biomol Screen; 2011 Sep; 16(8):805-17. PubMed ID: 21807962
[TBL] [Abstract][Full Text] [Related]
15. Clinically relevant orthotopic xenograft models of patient-derived glioblastoma in zebrafish.
Ai X; Ye Z; Xiao C; Zhong J; Lancman JJ; Chen X; Pan X; Yang Y; Zhou L; Wang X; Shi H; Zhang D; Yao Y; Cao D; Zhao C
Dis Model Mech; 2022 Apr; 15(4):. PubMed ID: 35199829
[TBL] [Abstract][Full Text] [Related]
16. Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions.
Sengupta R; Barone A; Marasa J; Taylor S; Jackson E; Warrington NM; Rao S; Kim AH; Leonard JR; Piwnica-Worms D; Rubin JB
Oncotarget; 2015 Jul; 6(21):18282-92. PubMed ID: 26286961
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
18. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
19. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.
Laramy JK; Kim M; Gupta SK; Parrish KE; Zhang S; Bakken KK; Carlson BL; Mladek AC; Ma DJ; Sarkaria JN; Elmquist WF
J Pharmacol Exp Ther; 2017 Nov; 363(2):136-147. PubMed ID: 28847917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
